Thibodeau
TL3 Regular · Stavanger, NO
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 26 January 2025 · last posted 2d · groups: journal-club
127Posts here
4Topics
1Solutions
5.4kLikes received
6.2kLikes given
31Badges
483Days visited
18kPosts read
Stated areas
Recent activity
Full stream-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #99 · Practice › Dosing & titration · 26 Jul 2026 · 0 likes When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a…
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #17 · Compounds › Tirzepatide · 24 Jul 2026 · 0 likes Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly…
-
Publication patterns in the BPC-157 literature, examined Replied, post #43 · Compounds › Repair & healing peptides · 23 Jul 2026 · 31 likes Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no…
-
Blinding yourself: practical methods and their limits Replied, post #44 · Research Methods › N-of-1 designs · 20 Jul 2026 · 0 likes Confounding in personal experiments: other things change when you start a medication (season, exercise, diet, stress). Documenting those confounders helps you…
-
Common supplements people ask about, assessed one at a time Replied, post #60 · Practice › Interactions · 17 Jul 2026 · 0 likes Coming back to post #58, because the follow-up matters more than the original answer. Two things before anyone answers the substance. First, the context in the first…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #37 · Compounds › Repair & healing peptides · 17 Jul 2026 · 13 likes post #36 is right about the mechanism and I think understates the practical bit. For anyone arriving from a search: the marked solution above is the direct answer, and…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #65 · Analytics › Home & field testing · 8 Jul 2026 · 15 likes Sample handling matters: if a sample is contaminated or degraded before testing, the test gives you the result for the degraded sample, not for fresh material. That is…
-
What I would want from a home test that does not exist yet Replied, post #31 · Analytics › Home & field testing · 8 Jul 2026 · 7 likes Colorimetric tests: colour intensity correlates with concentration, but the relationship is non-linear at extremes and the correlation depends on the exact conditions…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #34 · Evidence › Journal club · 7 Jul 2026 · 10 likes Session format: read the paper before posting. The discussion is much better when everyone has. Start with the estimand and population, then methods, then results, then…
-
Journal club: LEADER as the historical anchor Replied, post #100 · Evidence › Journal club · 6 Jul 2026 · 14 likes Worth separating two things that post #96 runs together. SURMOUNT-OSA (N Engl J Med 2024): Tirzepatide in obstructive sleep apnoea, using an objective physiological…
-
Tracking a shortage from primary sources rather than rumour Replied, post #88 · Access › Shortages · 6 Jul 2026 · 13 likes Picking up post #85: that is the part I would want checked first. Resuming after a gap: after a gap of days or a few weeks, most people resume at the dose they were on…
-
A structured critique template this community uses — a second dataset Replied, post #26 · Evidence › Study critique · 2 Jul 2026 · 18 likes Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished…